Knowing the GLP-1 contraindications is not box-ticking — it is what keeps a patient safe and your prescribing defensible. These medications are remarkably effective and generally well tolerated, but a small number of patients should never receive them, and a larger group needs careful screening before you write the prescription. This guide walks prescribers through the absolute contraindications, the relative cautions, a practical pre-prescribing screen, special populations, and the drug interactions that are easy to miss.
It is written for the moment of decision — the patient is in front of you, the medication looks like a good fit, and you need to confirm it is genuinely appropriate. For the wider clinical picture, this pairs with our complete prescriber’s guide to GLP-1 medications for weight management.
Two situations rule out GLP-1 receptor agonists entirely. Both appear in the class boxed warning and prescribing information (U.S. National Library of Medicine, 2025).
The first is a personal or family history of medullary thyroid carcinoma (MTC), or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). This warning stems from rodent studies in which GLP-1 agonists caused thyroid C-cell tumors. Whether this translates to humans is unresolved, but the labeling is unambiguous: these patients should not receive the drug, and a family history counts. How to explain that uncertainty to a patient without alarming them is covered in our guide to counseling patients on pancreatitis and thyroid risk.
The second is known serious hypersensitivity to the specific agent or any of its components. A prior serious reaction — anaphylaxis or angioedema — to semaglutide, tirzepatide, or an excipient rules that product out. In both cases, screening is simple but must actually be asked; neither red flag is visible without a direct question.
The two questions that cannot be skipped
“Has anyone in your family ever had thyroid cancer or a condition called MEN2?” and “Have you ever had a serious allergic reaction to a medication like this one?” Neither answer appears in a chart review, a lab panel or a physical exam. If they are not asked out loud, they are not screened.
Most screening happens in the grey zone of relative contraindications — situations that call for caution, extra counseling, or an alternative rather than an absolute no.
History of pancreatitis. Acute pancreatitis has been reported with GLP-1 therapy. A prior episode does not automatically forbid treatment, but it warrants a careful risk-benefit discussion and a low threshold to stop the drug and investigate if a patient develops severe, persistent abdominal pain.
Severe gastroparesis or significant GI motility disorders. Because these drugs slow gastric emptying by design, they can worsen pre-existing gastroparesis and should generally be avoided in that setting. For patients without a motility disorder, the same mechanism produces the ordinary nausea and constipation covered in managing GLP-1 gastrointestinal side effects.
Pregnancy and breastfeeding. GLP-1 agonists are not recommended in pregnancy; weight loss offers no benefit to a developing fetus and animal data raise concern. Advise discontinuation when pregnancy is planned or discovered. Because of the long half-life of the weekly agents, labeling generally advises stopping well before a planned conception.
Gallbladder disease. Rapid weight loss increases the risk of gallstones and cholecystitis; counsel patients on the symptoms and monitor accordingly.
History of diabetic retinopathy. In diabetic patients, rapid improvement in glycemic control has been associated with a temporary worsening of retinopathy, a signal seen in the semaglutide SUSTAIN-6 trial (Marso et al., 2016). Patients with a history of retinopathy warrant monitoring.
A short, consistent screen catches nearly every red flag above. Before prescribing a GLP-1 agent for weight management, confirm:
| Screen for | What you are ruling out |
|---|---|
| Personal or family history of MTC or MEN2 | Absolute contraindication |
| Prior serious reaction to a GLP-1 or excipient | Absolute contraindication (hypersensitivity) |
| History of pancreatitis | Relative contraindication — risk-benefit discussion |
| Gastroparesis or severe GI motility disorder | Relative contraindication |
| Pregnancy status and reproductive plans | Avoid in pregnancy; plan discontinuation before conception |
| Personal or family gallbladder disease; diabetic retinopathy | Cautions requiring counseling and monitoring |
| Current medications (insulin, sulfonylureas, oral contraceptives, oral drugs) | Interaction review (see below) |
| Eating-disorder history and mental-health status | Appropriateness and safety of weight-loss pharmacotherapy |
Pair the screen with baseline measurements — weight, BMI, blood pressure, and, where clinically indicated, a metabolic panel and HbA1c — so you have a reference point and a documented rationale. The FDA candidacy floor is a BMI of 30 or greater, or 27 or greater with at least one weight-related comorbidity.
Several groups are not contraindicated but need individualized judgment.
Older adults can benefit from GLP-1 therapy but are more vulnerable to volume depletion from nausea, vomiting, or reduced intake, and to loss of lean muscle mass. Slower titration, attention to protein intake, and monitoring for dehydration matter more here — see preventing muscle loss during GLP-1 therapy for the protein and resistance-training targets.
Renal and hepatic impairment. The agents themselves are not primarily cleared by the kidney, but the dehydration that can accompany significant GI side effects has precipitated acute kidney injury. Monitor renal function in patients with pre-existing impairment and counsel on hydration.
Type 1 diabetes. GLP-1 agonists are not a substitute for insulin and are not indicated for type 1 diabetes; use in this population is off-label and specialist-directed.
Eating disorders. A history of anorexia, bulimia, or other disordered eating calls for caution and often collaboration with mental-health care before using an appetite-suppressing medication.
Adolescents. Semaglutide (Wegovy®) is FDA-approved for adolescents aged 12 and older with obesity, but pediatric prescribing carries its own considerations and is often best coordinated with pediatric specialists. Verify the specific age indication for whichever agent you are considering.
The most important interactions trace back to two mechanisms: delayed gastric emptying and glucose-dependent insulin release (Drucker, 2018).
Oral contraceptives with tirzepatide. Tirzepatide can reduce the effectiveness of oral contraceptives, likely through delayed gastric emptying affecting absorption. The Zepbound® labeling advises patients on oral contraceptives to switch to a non-oral method or add a barrier method for four weeks after starting and after each dose increase (U.S. Food and Drug Administration, 2026). This is a common, easily missed counseling point in a population that includes many women of reproductive age — and because it resets at every escalation, it needs to be built into your tirzepatide titration schedule rather than mentioned once at initiation.
Insulin and sulfonylureas. On their own, GLP-1 agents rarely cause hypoglycemia because they stimulate insulin only when glucose is elevated. Combined with insulin or a sulfonylurea, however, hypoglycemia risk rises, and a dose reduction of the insulin or sulfonylurea is often warranted.
Other oral medications. Because gastric emptying is slowed, the absorption of some oral drugs can be affected. Use extra care with medications that have a narrow therapeutic index and monitor as appropriate.
Good documentation is the difference between a defensible decision and an exposed one. Patient selection is a clinical judgment, and the record should show that you made it deliberately.
At minimum, document the indication (BMI and any weight-related comorbidity), the screening you performed for absolute and relative contraindications, the counseling you provided on side effects and warning symptoms, any interaction adjustments, and the patient’s informed agreement to a long-term therapy. If you proceed despite a relative contraindication, note the risk-benefit reasoning explicitly. This record protects the patient by forcing a complete assessment, and it protects you if the decision is ever questioned.
Turn the checklist above into a template in your EMR rather than a memory exercise. A screening block that lists each item and forces an explicit yes or no produces two things at once: a faster visit, and a record that shows the screen actually happened. Practices setting this up from scratch will find the full workflow in how to build a medical weight-loss program.
Building this habit into a repeatable protocol is exactly what structured training instills — IAPAM’s certified GLP-1 weight management training gives prescribers ready-made screening and documentation frameworks so nothing is left to memory.
IAPAM’s GLP-1 certification training covers patient selection, titration, side-effect management, device and injection counseling, and the business of running a medical weight-management program — taught by practicing physician faculty.
Eligibility: MD/DO, NP, APRN/CRNA, PA, DMD/DDS, RN
What the program covers
A personal or family history of medullary thyroid carcinoma (MTC) or MEN2 syndrome, and a known serious hypersensitivity to the agent or its components. Both appear in the class boxed warning and rule the medication out entirely.
It is a relative contraindication, not an absolute one. A prior episode warrants a careful risk-benefit discussion and a low threshold to stop the drug and investigate if severe, persistent abdominal pain develops.
Largely yes — both share the MTC/MEN2 and hypersensitivity contraindications and the pancreatitis, gallbladder, and pregnancy cautions. A notable difference is that tirzepatide can reduce oral contraceptive effectiveness, requiring a backup method for four weeks after initiation and each dose increase.
No. They are not recommended in pregnancy and should be discontinued when pregnancy is planned or discovered. Because the weekly agents have a long half-life, labeling generally advises stopping well before a planned conception.
Tirzepatide can reduce the absorption and effectiveness of oral contraceptives. Advise patients to use a non-oral method or add a barrier method for four weeks after starting tirzepatide and after each dose escalation.
Older adults (dehydration and muscle-loss risk), patients with renal impairment, those with a history of gallbladder disease or diabetic retinopathy, and anyone on insulin or a sulfonylurea. These are cautions managed with monitoring and dose adjustments, not automatic exclusions.
Safe GLP-1 prescribing rests on a short, consistent screen: rule out the two absolute contraindications, weigh the relative ones, adjust for special populations and interactions, and document the reasoning. Done well, it takes only a few minutes and turns an effective medication into a genuinely safe one for the patient in front of you.
For the full workflow — selection, dosing, side-effect management, and program building — see our complete prescriber’s guide to GLP-1 medications. And to build repeatable screening and documentation protocols with confidence, IAPAM’s certified GLP-1 weight management training — backed by more than 20 years of training healthcare professionals and over 6,300 five-star reviews — gives you the clinical frameworks to prescribe safely.
See GLP-1 Certification Training Options
Disclaimer: This article is for informational and educational purposes only and does not constitute medical or prescribing advice. Contraindications and labeling change; always verify the current FDA-approved prescribing information for each agent and individualize care for every patient.
IAPAM Learning Lab
Patients are already asking about GLP-1s, injectables, PRP, lasers, and aesthetic treatments. Build the knowledge to have better clinical conversations now—on a schedule that works around your practice.
Need hands-on BOTOX® training instead? Explore IAPAM’s Botox training options →
Medical Weight Management Training
Build the clinical, operational, and business foundations to evaluate GLP-1 weight-management services for your practice—without handing your patient relationships to a corporate intermediary.
Explore GLP-1 Certification Training →Want to add Botox® training to your broader practice plan? Explore IAPAM’s Botox training options →
In order to have a successful aesthetic practice, you need to have effective advertising to attract people to your business.
This includes spending those
While Ozempic® has been proven effective in clinical trials, a potential reason for not losing weight on Ozempic® is related to dietary and lifestyle choices.
Failure to refrigerate the Ozempic® within the correct temperature range may result in reduced effectiveness and potential harm to the user.
Learn about the effects of stopping Ozempic® for diabetes & weight loss. Manage withdrawal & maintain health gains.
Request your Quick Start Checklist for Starting or Integrating a New GLP-1 for Weight Loss Guide.
Terms and conditions apply. Offer expires October 31.